Receive our newsletter – data, insights and analysis delivered to you
July 26, 2009

Landmark CAPS Treatment Ilaris set for European Approval

Ilaris, a treatment for the rare but potentially fatal auto-inflammatory disease cryopyrin-associated periodic syndrome (CAPS) has been recommended for approval in the EU. The treatment was given the thumbs up by the Committee for Medicinal Products for Human Use (CHMP), which reviews med

By cms admin

Ilaris, a treatment for the rare but potentially fatal auto-inflammatory disease cryopyrin-associated periodic syndrome (CAPS) has been recommended for approval in the EU.

The treatment was given the thumbs up by the Committee for Medicinal Products for Human Use (CHMP), which reviews medicines for the European Commission. If approved, the Novartis drug will be the only treatment in the EU for CAPS patients aged four years and older.

Ilaris is an advanced personalised medicine that directly targets the mutation in CAPS patients, which drives the overproduction of interleukin 1-beta (IL-1ß) causing widespread sustained inflammation and tissue damage.

Novartis Pharma head of global development Trevor Mundel said that by concentrating initially on a rare syndrome with a well-defined disease process such as CAPS, the company had been able to demonstrate a clear therapeutic advantage with Ilaris.

“Our focus now is to establish whether this could also provide a new approach to the treatment of other diseases involving a similar underlying process,” Mundel said.

The EU submission was supported by data showing that Ilaris produced rapid and sustained remission of symptoms in up to 97% of CAPS patients, with most responding from the first injection.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The recommendation comes shortly after approvals in the US and Switzerland where Ilaris was granted priority review based on its potential as a significant CAPS treatment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU